Illumina: Weak Backlog Support and Rising Competitive Pressures Undermine 2026 Outlook, Justifying Sell Rating

FierceBiotechGilead loosens ties to Arcus after TIGIT dream finally ends in phase 3 failure

FierceBiotechWith $50M from Flagship Pioneering, Serif strives to write new chapter for DNA medicines

Lonza NewsFDA-backed drug project tests modeling to reduce some human studies - Stock Titan

Thermo FisherSaladax Biomedical and Thermo Fisher Scientific Partner on Global Distribution of Drug Monitoring Assays - Clinical Lab Products

Thermo FisherTD Cowen Lowers Thermo Fisher (TMO) Price Target, Keeps Buy Rating - Yahoo Finance

Lonza NewsLonza Group AG stock (CH0013841017): Is its biopharma contract model resilient enough for new growth - AD HOC NEWS

FierceBiotechReplimmune ramps up layoffs to cover 60% of workforce amid ongoing fallout of FDA rejection

10x Genomics Blog10x Genomics debuts Atera, a new platform to redefine how biology is measured and understood at AACR 2026 - SelectScience

IlluminaClinical Genomic Market: Growth and Outlook Driven by Illumina, - openPR.com

Thermo FisherAssessing Thermo Fisher Scientific (TMO) Valuation After New PCR Launch And Data Partnerships - simplywall.st

Curiosis Inc.Working capital per share of Curiosis, Inc. – KRX:494120 - TradingView

WatersWaters Corporation Schedules First Quarter 2026 Earnings Conference Call - ChartMill